Carlsbad, CA, – June 19, 2006 – Micromet, Inc. (NASDAQ: MITI) today announced preliminary data from an ongoing phase 1 trial on MT103 (also known as MEDI-538) investigating the safety and tolerability of a continuous infusion of MT103 over a 4- to 8-week period at escalating dose levels in patients with relapsed, indolent Non-Hodgkin Lymphoma (NHL). The data were presented at the 11th Congress of the European Hematology Association.
